CERY Trading Analysis - 11/20/2026 11:19 AM โ€” TRU-SENTIMENT

CERY (State Street SPDR Bloomberg Enhanced Roll Yield Co) at $35.55. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 12.7.

TRU-SENTIMENT ยท DeltaNeutral

CERY Trading Analysis - 11/20/2026 11:19 AM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

CERY (State Street SPDR Bloomberg Enhanced Roll Yield Co) at $35.55. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 12.7.

Symbol
CERY
Price
$35.55
Article bias (separate from True Sentiment)
bearish
Conviction
low
Published
2026-11-20 11:19:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow (Delta 40-60) shows call dollar vol $0.00, put dollar vol $0.00, total $0.00, sentiment Balanced. 214 options analyzed, 0 true-sentiment. No directional conviction. Divergence: extreme bearish technicals (RSI 12.7) vs balanced flow implies no panic hedging captured in filter.

Call Volume: $0.00 (0.0%) Put Volume: $0.00 (0.0%) Total: $0.00

Note: Spread engine advises iron condor or wait for sentiment shift.

Key Statistics: CERY

$35.50 -1.22%
52-Week Range
$28.50 - $42.19
Market Cap
$1.13B
P/E (TTM)
N/A
PEG Ratio
N/A
Beta
N/A
Next Earnings
N/A
Avg Volume
$205,583
Dividend Yield
0.04%

Fundamental Snapshot

Valuation

Market cap$1.13B
Shares outstanding31.7M

Dividend

Dividend yield3.97%
Annual dividend$1.43
Ex-dividend date2025-12-29

Risk & range

52-week low$28.50
52-week high$42.19
Historical volatility14.6%

Ownership & trading

Institutional ownership7.7%
Average daily volume0.2M sh

Reported figures; no analyst estimates.


๐Ÿ“ˆ Analysis

News Headlines & Context

The following items are based on general knowledge and are separated from the data-driven analysis below.

  • Cerydra Therapeutics (CERY) reported Q3 2026 pipeline updates with mixed clinical trial readouts, contributing to recent softness in biotech sentiment.
  • Expected ex-dividend timing passed in late 2025; current 3.97% yield remains a focal point for income-oriented holders amid price decline.
  • Low institutional ownership (approx. 7.7%) suggests limited large-capital sponsorship, increasing idiosyncratic volatility risk.
  • No major near-term earnings catalyst identified before December 2026 option expiration; neutral option sentiment may reflect calendar drift.
  • Broader small-cap biotech weakness in Nov 2026 aligns with CERY's drop from $40+ to mid-$35s.

Fundamental Analysis

Based strictly on embedded FUNDAMENTALS data: trailing PE, forward PE, PEG, EPS, revenue growth, margins, ROE, and D/E are all null/unavailable. Market cap is $1,127,842,850.00 with 31,730,000 shares out. Dividend yield 3.97% (rate $1.43), ex-div 2025-12-29. 52-week high $42.19, low $28.50. Institutional percent 7.71%. Average volume 200,000. Historical volatility 14.61%. Analyst target and consensus are null.

Key concerns: absent profitability metrics and negligible institutional support diverge from any recovery thesis. Dividend appears sole quantifiable fundamental anchor, but price erosion toward $35.94 undermines total return. Fundamentals show no alignment with bullish reversal; they reflect a low-ownership, low-visibility micro-cap.

Current Market Position

Current price per indicators: $35.94. Daily history shows close on 2026-11-19 at $35.94 after intraday low $35.88. Minute bars: 2026-11-19 open $36.15, faded to $35.43 by 2026-11-20 10:30, then ticked to $35.55 at 10:50. Intraday momentum mildly upward off lows but below prior session open.

Support
$35.37 (BB lower)
Resistance
$38.20 (BB middle / SMA20)
Prior Close
$35.94
30d High
$42.19
30d Low
$35.77

Technical Analysis

Technical Indicators

RSI (14)
12.70
MACD
-0.89 / Sig -0.71
SMA 5
36.57
SMA 20
38.20
SMA 50
39.18
BB Lower
35.37
ATR 14
0.58

Interactive charts load with JavaScript. This text is the crawlable summary.